Merck Buys Cidara In $9.2 Billion Deal—Here’s What They’re Really After!

Merck & Co., Inc.’s third-quarter performance demonstrates its commitment to leveraging scientific advances to deliver value in the healthcare space. The company’s revenue for the quarter reached $17.3 billion, a growth of 4% despite foreign exchange headwinds. This growth was primarily driven by the continued strength of its oncology segment, notably the drug KEYTRUDA, which saw an 8% increase in sales, contributing $8.1 billion. Several factors underscore Merck’s positive performance. The company’s strategic acquisition of Verona Pharma positions it to further capitalize on growth opportunities, specifically in the realm of chronic obstructive pulmonary disease with OHTUVAYRE, a first-in-class maintenance treatment. Additionally, Merck’s diverse pipeline, which now features approximately 80 Phase III trials, underpins its potential for sustained growth. The strengthening of its Phase III studies and recent regulatory approvals, such as KEYTRUDA QLEX and supplemental approvals for WINREVAIR, further highlight the robust nature of Merck’s portfolio.